Reply from authors re: Nicolas mottet. Intermittent androgen deprivation in prostate cancer: Is everything so clear? Eur urol 2013;63:121-2: Intermittent androgen deprivation in advanced prostate cancer: An optional treatment regimen

摘要

Because of the limited duration of response to androgen deprivation therapy (ADT) in treatment of prostate cancer (PCa) and because of the adverse effects (AEs) of castration with deterioration in health-related quality of life (QpL), the FinnProstate Study VII (FPVII) was planned in the 1990s to compare intermittent androgen deprivation (IAD) and continuous ADT (CAD) in treatment of advanced PCa in terms of time to progression, overall survival, PCa-specific survival, time to treatment failure, and changes in QpL. Our interim analysis showed that patients with advanced PCa, having high tumour burden, high prostate-specific antigen (PSA) levels, high alkaline phosphatase levels, or metastatic disease with numerous skeletal hot spots did not show adequate biochemical PSA response to ADT, were not candidates for IAD, and were excluded from randomisation and further trial [1].